We can’t show the full text here under this license. Use the link below to read it at the source.
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
New Evidence and Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Kidney Disease in Diabetes
AI simplified
Abstract
SGLT2 inhibitors and GLP-1 receptor agonists may reshape diabetic kidney disease management, providing distinct cardiorenal benefits.
- Diabetic kidney disease (DKD) significantly increases the risk of end-stage kidney disease and cardiovascular mortality.
- Conventional therapies, including certain inhibitors, leave substantial residual risk in DKD patients.
- SGLT2 inhibitors may mitigate glomerular hyperfiltration and lower heart failure risk.
- GLP-1 receptor agonists are associated with reductions in albuminuria and atherosclerotic cardiovascular events.
- Indirect comparisons suggest SGLT2 inhibitors could offer greater protection against kidney function decline, though direct trials are needed.
- Combination therapy may enhance treatment efficacy, but further studies are required to determine optimal strategies.
AI simplified
Key numbers
30%
Reduction in Kidney Events
Risk reduction in kidney events from CREDENCE trial
39%
Risk Reduction in Kidney Failure
Risk reduction in DAPA-CKD trial
24%
Reduction in Kidney Failure Risk
Risk reduction in FLOW trial